Recent studies have shown that STAT3 pathway activation participates in the pathophysiological development of DCM, and inhibition of STAT3 attenuates cardiomyopathy in STZ-induced T1DM [37, 47]. The gene discussed is STAT3; the disease is cardiomyopathy.